Quest Diagnostics Incorporated
DGX · Price history
Price at last available close
$245.62
+$8.00 (+3.37%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Quest Diagnostics Incorporated
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients.
How they make money
Quest Diagnostics provides diagnostic information services by operating a network of clinical laboratories that perform testing for physicians, hospitals, health plans, employers, and consumers. The company generates revenue primarily through the volume of diagnostic tests processed and the associated fees for these clinical laboratory services.
Products & services
Diagnostic testing services including routine, non-routine, and Advanced Diagnostics (oncology, cardiometabolic, brain health, autoimmune, women's health, and genetics), healthcare IT solutions, and risk assessment services for insurers.
Brands & revenue mix
Primary brand for clinical laboratory and diagnostic services.
Separate brand revenue is not available in this research.Source
Blood test brand for aiding the diagnosis of Alzheimer’s disease.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Laboratory equipment and reagent manufacturers — The company relies on various third-party suppliers for diagnostic equipment, reagents, and medical supplies; specific supplier names are not disclosed.Source
Business relationships & partnerships
- Google Cloud — A collaboration focused on data analytics and generative AI to streamline data management and personalize experiences for patients and providers.Source
Competitors
- Laboratory Corporation of America Holdings (LabCorp) — Direct competitor in the clinical laboratory and diagnostic information services market.Source
Strengths
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
37
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
65
Fair
Financial Strength
60
Business Quality / Moat
67
Management
84
Growth Quality
35
Risk / Durability
80
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
27
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
35/100
Building Historical Record
Model Score 35/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Recent buyback activity is present
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for DGX
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can DGX maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is DGX's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is DGX's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What future growth or profitability would be needed to justify DGX's current valuation?
Essential Investment Snapshot
Wall Street Score
37
Opportunity Score
27
Market Cap
$27.11B
P/E Ratio
24.6
EPS
$9.54
52-Week High
$248.84
52-Week Low
$171.18
Beta
0.54
Intrinsic Value
$152.52
Analyst Target
$255.00
Shares Outstanding
113.0M
Total Revenue
$11.56B
Total Debt
$6.38B
Dividend Yield (TTM)
1.38%
Liquidation Value / Share
$69.19
Dividend / Share (TTM)
$3.38
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Building upward momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for DGX
Detected from reported data — verify before acting.Dividend history reported
Dividend payments are recorded. Review the dates and regular/special classification below; past payments do not guarantee future dividends.
Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on DGX.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Extensive national network of clinical laboratories.
- +Strong Advanced Diagnostics portfolio.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Diagnostics & Research industry.
- −Reimbursement rate pressure from government and private payers.
- −Regulatory compliance and changes in healthcare laws.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
8 historical score records availablePrevious Score
37
Oct 1, 2026
Change
-0.1
points
Current Score
37
Oct 20, 2026
Category Changes
DGX decreased 0.1 points because some fundamentals weakened.
Projected Score
Projected Score
39
Projected Change
+2.2 points
Preliminary comparable-period financial changes suggest improvement of approximately 2.2 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
OvervaluedCurrent Price
$245.62
Model Intrinsic Value
$152.52
Difference
+$93.10
+61.0% vs IV
Margin of Safety
-61.0%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.56B | $11.04B | $9.87B | $9.25B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $7.73B | $7.51B | $6.63B | $6.20B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $3.83B | $3.52B | $3.24B | $3.07B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $2.02B | $1.97B | $1.77B | $1.61B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $2.20B | $1.92B | $1.90B | $1.81B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $2.23B | $2.19B | $1.89B | $1.73B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $1.64B | $1.60B | $1.35B | $1.26B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $262.0M | $277.0M | $226.0M | $163.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $1.42B | $1.36B | $1.19B | $1.16B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $320.0M | $314.0M | $273.0M | $248.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $1.06B | $992.0M | $871.0M | $854.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $9.54 | $8.87 | $7.80 | $7.59 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 110M | 111M | 111M | 112M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 112M | 113M | 113M | 113M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$3.04B
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$2.84
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-0.0%
Cash Change
+96.2%
Margin Change
+0.3 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included revenue growth, EPS growth, cash levels, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 10.2%. EPS increased 15.0%. Cash increased 96.2%. Total debt was essentially unchanged. Net income margin improved by 0.3 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
12
Smart Money
12
Number of Gurus
1
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Log in to view dividend history.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
8 historical recordsHistorical Score Chart
3 of 8 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - Diagnostics & ResearchNews
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
PRIVACY ALERT: AWKO Law LLP Investigates Quest Diagnostics for Data Breach of Patient Records
Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term
Quest Diagnostics (DGX) Q3 Earnings and Revenues Beat Estimates
Rumor Mill · DGX
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial